Pharmaceuticals company Bajaj Healthcare announced Q4FY26 & FY26 results Financial Highlights: Revenue from operations: For Q4FY26, revenue from operations stood at Rs 15,305.75 lakh, representing a decline of 5.06% QoQ from Rs 16,122.27 lakh in Q3FY26 and a marginal drop of 0.92% YoY from Rs 15,447.25 lakh in Q4FY25. For FY26, revenue was Rs 61,103.14 lakh, growing by 12.61% YoY compared to Rs 54,260.24 lakh in FY25. Total Income: Recorded at Rs 15,601.37 lakh in Q4FY26, down by 4.21% QoQ from Rs 16,286.98 lakh in Q3FY26, and a decrease of 7.16% YoY from Rs 16,804.41 lakh in Q4FY25. For FY26, total income reached Rs 61,816.53 lakh, reflecting a 10.00% YoY increase from Rs 56,200.68 lakh in FY25. Profit / (Loss) Before Tax: The company reported a loss before tax of Rs 2,080.88 lakh in Q4FY26, compared to a profit of Rs 1,924.46 lakh in Q3FY26 and a profit of Rs 1,172.20 lakh in Q4FY25. This loss was primarily driven by an exceptional item charge of Rs 3,324.66 lakh. For FY26, profit before tax stood at Rs 2,892.30 lakh, a decline of 37.13% YoY against Rs 4,600.77 lakh in FY25. Total Profit / (Loss) for the period / year: The company posted a net loss of Rs 2,285.06 lakh in Q4FY26, compared to a net profit of Rs 1,567.38 lakh in Q3FY26 and a net profit of Rs 1,117.78 lakh in Q4FY25. For FY26, net profit was Rs 1,576.61 lakh, down by 60.08% YoY from Rs 3,949.55 lakh in FY25. Business Highlights: Segment-wise Performance: The company identifies only one reportable segment, i.e., "Pharmaceuticals", as its pharmaceutical products (formulations and active pharmaceutical ingredients components) are interlinked and interdependent. Dividend Announcement: The Board of Directors recommended a Final Dividend at the rate of 30% of the Face Value of Rs 5/- each, amounting to Rs 1.50/- per equity share for the financial year 2025-26, subject to shareholder approval. Exceptional Item (Reversal of Income): During Q4FY26, the company reversed income recognized in an earlier year amounting to Rs 3,324.66 lakh. This reversal was due to ongoing regional instability in the Middle East, which prevented a customer from meeting the committed timeline for a Transfer of Technical Know-how arrangement. Discontinued Operations & Asset Sale: The company successfully sold a unit situated at plot no. L-9/3 during Q4FY26. This was part of an earlier Board approval to sell/dispose of specific undertakings and vacant industrial lands on a going concern basis. Preferential Allotment and Fund Utilization: The Board approved the allotment of 20,79,409 fully paid-up Equity Shares at an issue price of Rs 338 per share upon the conversion of warrants, receiving the balance 75% payment of Rs 5,271.30 lakh. Out of the total Rs 20,497.00 lakh raised through the allotment of equity shares and warrants, the company has utilized Rs 17,300.18 lakh (Rs 15,000.00 lakh for repayment of loan, Rs 315.90 lakh for Capital Expenditure, and Rs 1,984.28 lakh for general corporate purposes). Acquisition Update: In April 2025, the company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis for a total consideration of Rs 1,085 lakh. An application filed with the NCLT, Mumbai, seeking certain reliefs and concessions for the effective implementation of the takeover is currently pending as of March 31, 2026. Auditor Appointments: The Board approved the appointment of M/s. JCR & Co. LLP as Internal Auditors and the re-appointment of M/s. V.J. Talati & Co. as Cost Auditors for FY27. Anil Jain, Managing Director said: “The quarter was marked by a challenging operating environment driven by continued price erosion in domestic APIs, early impacts of geopolitical disruptions in West Asia including elevated raw material prices. While revenue remained broadly stable on a YoY basis despite high teens volume growth, Profit After Tax from continuing operations before exceptional items registered healthy growth of 19% YoY, reflecting the strength of our operational discipline, cost management, and continued focus on profitability despite external headwinds. FY26 revenue grew 12.6% YoY, driven by strong API export growth of 51.6% YoY as we witnessed healthy traction across the EU, UK, LATAM, and other regulated markets, coupled with sustained momentum in the formulations business which also recorded 12.6% YoY growth. EBITDA and overall profitability improved during the year, with PAT margin from continuing operations before exceptional items rising to 8.8% compared to 7.9% in FY25 The formulations business continued to scale meaningfully within the overall business mix, reinforcing diversification benefits, while the CDMO business also gained traction with supplies ramping up steadily. We expect this segment to contribute more meaningfully in the coming quarters as commercial execution continues to expand. The Company also made notable progress on the regulatory and product development front during the year. We filed 41 DMFs during the quarter, taking cumulative filings to 110, further strengthening our presence in regulated markets. The Company has reversed the income recognized in earlier financial year for transferring of technical know-how to manufacture one of the products for a party in Middle East region. The customer was not able to meet its financial commitment, due to delay in getting regulatory approvals for the project. Now due to recent ongoing regional instability in Middle East, the company has decided to cancel the arrangement and reversed the income. Looking ahead, we remain focused on strengthening our core API business and achieving export-led growth while scaling our formulations business with an emphasis on higher-value products. We are accelerating efforts in peptides, oncology, and CNS, supported by continued investments in manufacturing, capacity expansion, and R&D-led; innovation. In parallel, we are also strengthening our product pipeline to build a more diversified revenue base. With this integrated approach, Bajaj Healthcare is well positioned to deliver sustainable long-term value for stakeholders.” Result PDF